These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 36831044)

  • 21. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Deleterious
    Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L
    Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
    Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Alonso-Viteri S; Khosravi-Shahi P
    Clin Lung Cancer; 2021 Sep; 22(5):381-389. PubMed ID: 33875382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
    Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
    Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
    Lim JU; Yoon HK
    Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
    Duchemann B; Remon J; Naigeon M; Mezquita L; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Auclin E; Desnoyer A; Besse B; Chaput N
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.
    Baglivo S; Bianconi F; Metro G; Gili A; Tofanetti FR; Bellezza G; Ricciuti B; Mandarano M; Teti V; Siggillino A; Reda MS; Chiari R; Pistola L; Sidoni A; Minotti V; Roila F; Ludovini V
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.
    Wu X; Chau YF; Bai H; Zhuang X; Wang J; Duan J
    Front Oncol; 2022; 12():1099304. PubMed ID: 36761426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
    Zhang S; Yang L; Yang Y; Xin Y; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Pistamaltzian NF; Georgoulias V; Kotsakis A
    Expert Rev Respir Med; 2019 May; 13(5):435-447. PubMed ID: 30869543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
    Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Jung CY; Antonia SJ
    Tuberc Respir Dis (Seoul); 2018 Jan; 81(1):29-41. PubMed ID: 29332322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.